{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} Unexpected Success for a TKI in Activating Anticancer Innate Immunity

Activity Steps

Purpose of Activity

To provide information on tyrosine kinase inhibitors (TKI), with emphasis on cabozantinib.

Learning Objectives/Outcomes

After completing this continuing education activity you will be able to:

  1. Distinguish the evidence supporting the role of the innate immune system in antitumor response.
  2. Summarize study results identifying cabozantinib as a modulator of neutrophil-mediated antitumor innate immunity.
Price: $12.95


  • ANCC 1.0 CH
  • DC - BON 1.0 CH
  • FL - BON 1.0 CH
  • GA - BON 1.0 CH

Lippincott Professional Development is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation. This activity is also provider approved by the California Board of Registered Nursing, Provider Number CEP 11749. Lippincott Professional Development is also an approved provider of continuing nursing education by the District of Columbia Board of Nursing, Florida Board of Nursing, and Georgia Board of Nursing, #50-1223.

Test Code: OT1118
Published: Nov 2018
Expires: 9/3/2021
Sources: Oncology Times
Required Passing Score: 7/10 (70%)
Authors: Richard Simoneaux
Categories: Cancer , Oncology
Specialties: Oncology